Taking responsibility seriously: SCHOTT Pharma releases first sustainability report

Friday, January 26, 2024, Mainz, Germany

  • Digital report illustrates commitment to address sustainability as a business priority

  • Transparency for stakeholders on the company’s holistic understanding of sustainability

  • 100% green electricity and 60 % reduction of CO2 emissions in Scope 1 & 2 already achieved

Not only human health matters to SCHOTT Pharma but also sustainable development and business governance. As a global leader in drug containment solutions and delivery systems for injectable drugs, the company unveils its first Sustainability Report for fiscal year 2023, reaffirming the company's commitment to sustainable business practices and corporate responsibility. The comprehensive report, aligned with Global Reporting Initiative (GRI) Standards, provides a holistic view of the company's sustainability activities. “At SCHOTT Pharma, we believe in sustainability as a key driver to achieve our strategic goals. Together with our partners and customers, we’re taking a proactive stance in addressing the challenges posed by a rapidly evolving world,” explains Dr. Almuth Steinkühler, CFO of SCHOTT Pharma. “With this report, we want to create transparency for our stakeholders and take them with us on our sustainability journey.”
Woman in cleanroom clothing holding a pharmaceutical vial for quality control.
SCHOTT Pharma released its first Sustainability Report as a publicly listed company. The comprehensive report, aligned with Global Reporting Initiative (GRI) Standards, provides a holistic view of the company's sustainability activities. Photo: SCHOTT/ Oana Szekely

The company’s Sustainability Report 2022/23 is structured thematically along the chapters of Business Responsibility, Workforce Responsibility, Social Responsibility, and Environmental Responsibility. The key highlights of the Sustainability Report include:

  • The mission of SCHOTT Pharma: Emphasizing the core mission, "Because human health matters," the report underscores SCHOTT Pharma's pivotal role in providing high-quality product solutions to safely store and administer systemically relevant medicine. Therefore, the commitment to the quality and security of the supply chain represents a sustainable contribution to global health for the greater good. More than 25,000 injections per minute are provided to patients worldwide through a SCHOTT Pharma product, including syringes, cartridges, vials, and ampoules.

  • Climate Neutrality 2030: The company outlines its commitment to achieving climate-neutral production by 2030. SCHOTT Pharma is reporting its externally certified Scope 1 and 2 emissions as well as a first-time calculation of its Scope 3 emissions. The report provides a comprehensive overview of the past fiscal year's performance. Highlights include using 100% green electricity at all sites and reducing CO2 emissions by 60% from 2019. The fiscal year 2023 also already entailed preparations for the next milestone on SCHOTT Pharma’s climate journey: As part of the SCHOTT Group, the climate goals were prepared for validation by the Science-Based Targets initiative (SBTi). In November 2023, the Group received the confirmation of its climate actions to be in line with the Paris Agreement, thereby establishing a strong foundation for its future climate action trajectory.

  • Social Responsibility: The report highlights the company’s dedication to social responsibility, emphasizing an attractive working environment as well as diversity, equality and inclusion. Following its commitment to diverse team compositions related to gender, internationality and educational backgrounds, the company strives for an increase of women in exempt leadership positions to more than 30%.

  • Corporate Governance: The report underscores the commitment to strong corporate governance, anti-corruption measures, and clear policies aligning with the principles of the United Nations Global Compact for sustainable and responsible business. Additionally, the company takes actions to see the same values reflected along its value chain. The company drives this commitment via its Supplier Code of Conduct, risk assessments related to human rights and business conduct as well as via supplier rankings and close cooperation with its supply chain stakeholders.

  • Holistic Sustainability View: SCHOTT Pharma embraces a holistic view of sustainability, addressing waste management, water conservation, environmental protection, occupational safety, and health initiatives as its material topics based on a thorough double-materiality analysis. The materiality of sustainability issues was evaluated in a series of stakeholder workshops considering both inside-out impacts as well as outside-in factors.

„By releasing this comprehensive Sustainability Report, we aim to openly communicate our sustainability initiatives and achievements,” adds Arne Kloke, Head of Sustainability SCHOTT Pharma. “We remain dedicated to driving positive change, contributing to global health, and maintaining the highest standards of corporate responsibility.”

The full Sustainability Report can be accessed on the SCHOTT Pharma website. In addition, the SCHOTT Pharma Annual Report features an abbreviated non-financial declaration addressing sustainability topics as well as EU Taxonomy disclosures as part of the company's annual statements.


About SCHOTT Pharma

Because human health matters. That is why SCHOTT Pharma designs solutions grounded in science to ensure that medications are safe and easy to use for people around the world. The portfolio comprises drug containment solutions and delivery systems for injectable drugs ranging from prefillable glass and polymer syringes to cartridges, vials, and ampoules. Every day, a team of over 4,600 people from over 60 nations work at SCHOTT Pharma to contribute to global healthcare. The company is represented in all main pharmaceutical hubs with 16 manufacturing sites in Europe, North and South America, and Asia. With over 1,000 patents and technologies developed in-house and a state-of-the-art R&D center in Switzerland, the company is focused on developing innovations for the future. SCHOTT Pharma AG & Co. KGaA is headquartered in Mainz, Germany and listed on the Frankfurt Stock Exchange as part of the SDAX. It is part of SCHOTT AG, which is owned by the Carl Zeiss Foundation. In light of this spirit, SCHOTT Pharma is committed to sustainable development for society and the environment and has the strategic goal of becoming climate-neutral by 2030. Currently, SCHOTT Pharma has over 1,800 customers including the top 30 leading pharma manufacturers for injectable drugs and generated revenue of EUR 899 million in the fiscal year 2023. Further information at www.schott-pharma.com.

Contact us

For more information about this media release, please contact me.

Contact us
Joana Kornblum - Public Relations Manager
Joana Kornblum

Manager Corporate Communications